Figure 2.

A 51-year-old woman with metastatic pancreatic neuroendocrine tumor (G2; Ki-67, 5%). The patient was previously treated with 2 cycles of ¹⁷⁷Lu-DOTATATE PRRT (cumulative activity, 14.8 GBq). The baseline ⁶⁸Ga-DOTATATE PET/CT (A, MIP image; B, fused PET/CT) before ¹⁷⁷Lu-DOTATATE demonstrated somatostatin receptor avid multiple metastases. Follow-up ⁶⁸Ga-DOTATATE PET/CT (C, MIP image; D, fused PET/CT) performed 2 months after 2 cycles of ¹⁷⁷Lu-DOTATATE showed stable disease. The patient was then admitted for ¹⁷⁷Lu-DOTA-EB-TATE. Follow-up ⁶⁸Ga-DOTATATE PET/CT (E, MIP image; F fused PET/CT) performed 2 months after ¹⁷⁷Lu-DOTA-EB-TATE showed partial response (administered activity, 3.85 GBq). On follow-up, the disease remained stable with progression-free survival of 15 months.